Holen Sie sich die Stockscreener-App
134.53
1.79%
2.36
Vorhandelsmarkt:
134.53
Insmed Inc Aktie (INSM) Neueste Nachrichten
Intraday pattern recognizer results for Insmed IncorporatedPortfolio Profit Report & High Win Rate Trade Alerts - Newser
Predicting Insmed Incorporated trend using moving averages2025 Big Picture & Short-Term High Return Strategies - Newser
Insmed's 1.79% Surge on $0.27B Volume Ranks 365th as Sector Trends Drive Quiet Rally - AInvest
Using R and stats models for Insmed Incorporated forecastingJuly 2025 Volume & Community Consensus Picks - Newser
Custom watchlist performance reports with Insmed IncorporatedJuly 2025 Catalysts & Smart Allocation Stock Reports - Newser
How sentiment analysis helps forecast Insmed IncorporatedPortfolio Value Summary & Consistent Profit Trading Strategies - Newser
Is Insmed Incorporated stock entering bullish territoryCEO Change & Consistent Growth Equity Picks - Newser
Is this a good reentry point in Insmed IncorporatedWeekly Trade Analysis & Accurate Buy Signal Alerts - Newser
Is This a Bottoming Phase for Insmed Incorporated getLinesFromResByArray error: size == 0 - 더경남뉴스
Exit strategy if you’re trapped in Insmed IncorporatedAnalyst Upgrade & Free Expert Verified Stock Movement Alerts - Newser
Institutional scanner results for Insmed Incorporated2025 Growth vs Value & Weekly Market Pulse Updates - Newser
Will Insmed Incorporated outperform the marketPortfolio Value Summary & Intraday High Probability Setup Alerts - Newser
Has Insmed Incorporated found a price floorDividend Hike & Low Risk Investment Opportunities - Newser
Bronchiectasis Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights By DelveInsight | SolAeroMed, Insmed, NovaBiotics Ltd, Synspira Therapeutics, Parion - Barchart.com
Is Insmed Incorporated showing signs of accumulationTake Profit & Growth Focused Stock Pick Reports - Newser
Developing predictive dashboards with Insmed Incorporated dataPortfolio Return Report & AI Powered Market Entry Ideas - Newser
Relative strength of Insmed Incorporated in sector analysisTrade Exit Summary & Risk Controlled Stock Alerts - Newser
Using data tools to time your Insmed Incorporated exitMarket Trend Report & Community Verified Watchlist Alerts - Newser
Analyzing Insmed Incorporated with risk reward ratio chartsPortfolio Gains Report & Community Driven Trade Alerts - Newser
Is it time to cut losses on Insmed IncorporatedQuarterly Profit Summary & Real-Time Buy Zone Alerts - Newser
Is This a Bottoming Phase for Insmed Incorporated2025 Support & Resistance & Weekly Watchlist for Consistent Profits - beatles.ru
Insmed revenue set to surge on Brinsupri launch - S&P Global
What to do if you’re stuck in Insmed IncorporatedJuly 2025 Selloffs & Free High Return Stock Watch Alerts - Newser
What Fibonacci levels say about Insmed Incorporated reboundJuly 2025 Analyst Calls & Precise Buy Zone Tips - Newser
Full technical analysis of Insmed Incorporated stockPrice Action & Weekly Market Pulse Alerts - Newser
Insmed Shares Dip 2.70% With 349th-Ranked $260M Volume as FDA-Approved Brinsupri Ignites 2035 $15B Sales Outlook and Bullish Technical Signals Emerge - AInvest
Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight - GlobeNewswire Inc.
Investor's Guide: INSMED INC (INSM) Passes Value Investor Model - AInvest
Why Insmed Incorporated stock attracts strong analyst attentionWeekly Market Outlook & Expert Curated Trade Setups - Newser
Will Insmed Incorporated bounce back from current support2025 Pullback Review & High Accuracy Trade Signal Alerts - Newser
FDA-Approved Insmed Drug Drives 0.54 Stock Drop as 280M Volume Ranks 391st Long-Term Growth Hopes Face Reimbursement and Adoption Risks - AInvest
Is Insmed Incorporated Forming a Bottom Pattern2025 EndofYear Setup & Reliable Intraday Trade Alerts - beatles.ru
Insmed divulges new cathepsin C inhibitors - BioWorld MedTech
How FDA Approval of BRINSUPRI for NCFB at Insmed (INSM) Has Changed Its Investment Story - Yahoo Finance
Insmed Executives Sell Shares Amidst Strong Earnings Call and Promising Clinical Trials - AInvest
Insmed's Bright Future: Buy Rating Confirmed by Brinsupri Approval and Strategic Growth Prospects - AInvest
Insmed Shares Climb 2.43% on $290M Volume, Rank 301st in Market Activity - AInvest
Insmed To Present at September Investor Conferences - Eastern Progress
Insmed stock hits 52-week high at 130.18 USD - Investing.com
Insmed Incorporated to Present at Two Investor Conferences in September. - AInvest
1.70%
1.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):